News | Pulmonary Embolism | January 29, 2024

Breakthrough Research Identifies Predictors of Venous Thromboembolism after Pulmonary Resection for Lung Cancer

Researchers uncover critical factors for improved patient safety in lung cancer resection– An analysis of the STS general thoracic surgery database 

Researchers uncover critical factors for improved patient safety in lung cancer resection– An analysis of the STS general thoracic surgery database

January 29, 2024 — In patients who undergo pulmonary resection for lung cancer, a major potential postoperative complication is venous thromboembolism (VTE)—a condition that develops when a blood clot forms in a vein—which can lead to part of the clot breaking off and lodging in the lung, resulting in a pulmonary embolism (PE). 

New research presented at The Society of Thoracic Surgeons’ Annual Meeting found that patients with postoperative PE had increased 30-day mortality, reintubation, and readmission rates. The risk factors for postoperative embolism included Black race, interstitial fibrosis, advanced-stage disease requiring bilobectomy or pneumonectomy, and increased operative duration. 

“Because the predominating risk factors for postoperative VTE identified in this analysis are non-modifiable, and because VTE-associated mortality is increased, enhanced awareness and targeted perioperative prophylactic measures should be considered in these high-risk cohorts,” said the study’s lead author, Andrea L. Axtell, MD, MPH, an assistant professor of surgery at the University of Wisconsin School of Medicine and Public Health

Dr. Axtell’s team analyzed information from STS’s General Thoracic Surgery Database (GTSD), a powerful resource that contains more than 700,000 procedure records and has more than 1,000 participating surgeons. They looked at anonymous results for 57,531 adult patients who underwent pulmonary resection—removal of all or part of a lung—between January 2009 and June 2021. 

Of these patients, 758 developed blood clots that moved to the lungs after surgery. “Patients who developed PE were more likely to be Black—12% versus 7% of patients of other races,” the authors observed. Vulnerable patients were also more likely to have interstitial fibrosis, a condition involving scarring and inflammation of the lung. In addition, those who had more advanced disease, and those who underwent bilobectomy (removal of two lung lobes) or pneumonectomy (removal of a whole lung), were more likely to develop PE. 

In this contemporary analysis of the GTSD, the research team identified a 2.5% occurrence of postoperative VTE and a 1.3% occurrence of postoperative PE in patients undergoing a first-time pulmonary resection for lung cancer. 

“Trends over time demonstrate the incidence of postoperative VTE to be largely unchanged over the 12-year study period; however, the associated mortality rate slowly decreased from 20%  in 2009 to 8% in 2018,” said Dr. Axtell. 

The researchers found no difference in PE risk based on how well the lungs functioned before surgery, cancer cell type (histology), or whether or not the patients received chemotherapy before surgery. 

“Black race has previously been identified as a predisposing factor for VTE and was confirmed in our analysis,” Dr. Axtell said, noting that a prior analysis by the Centers for Disease Control and Prevention found that Black Americans had a 40% higher incidence of VTE overall compared with white Americans, and a 2.8-fold odds increase of VTE in patients with lung cancer specifically. 

She further explained, “While this difference is likely multi-factorial, previous investigations have suggested genetic variability, socioeconomic factors, and health disparities in access to high-volume, subspecialized care. By increasing awareness of the increased risk for VTE in Black patients, the team hopes to encourage more focused preventative measures in these patients.” 

Extra steps for patients at increased risk for embolism after lung cancer surgery may include additional imaging, such as ultrasound of the legs, where blood clots may form or extended courses of blood thinning medications to prevent the occurrence of clot formation. 

For more information: https://www.sts.org/ 

Find more STS 2024 conference coverage here


Related Content

News | Pulmonary Embolism

October 25, 2023 — Data from the REAL-PE study was presented today at Transcatheter Cardiovascular Therapeutics(TCT) ...

Home October 25, 2023
Home
News | Pulmonary Embolism

June 30, 2023 — Of approximately 250,000 Americans diagnosed with acute pulmonary embolism, or PE, in emergency ...

Home June 30, 2023
Home
News | Pulmonary Embolism

March 10, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home March 10, 2023
Home
News | Pulmonary Embolism

February 22, 2023 — RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and ...

Home February 22, 2023
Home
News | Pulmonary Embolism

November 17, 2022 — Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, announced the ...

Home November 17, 2022
Home
News | Pulmonary Embolism
February 16, 2022 – Inari Medical, Inc. has announced that the first patient has been enrolled in PEERLESS, a ...
Home February 16, 2022
Home
News | Pulmonary Embolism

February 14, 2022 — Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the ...

Home February 14, 2022
Home
News | Pulmonary Embolism

August 9, 2021 — Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative ...

Home August 09, 2021
Home
News | Pulmonary Embolism

October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world ...

Home October 23, 2020
Home
News | Pulmonary Embolism

October 18, 2019 —­­ Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than ...

Home October 18, 2019
Home
Subscribe Now